2025/0384(COD) · Committee Report Adopted
15 submissions from 13 organizations told the European Commission what they think about this file. Here is what each of them said, in their own words.
The Commission lists 78 submissions on this file. Shown here: the 15 from organizations. Not shown, by design: submissions from private individuals, which we never publish, and anything filed since our last weekly refresh.
9 submissions from industry — companies and their trade associations — against 1 from civil society: NGOs, consumer organizations, environmental groups and trade unions. That is 9 industry submissions for every one from civil society.
Groupings use the respondent type each organization selected when filing. Counting submissions, not organizations — a body that filed twice is counted twice.
The file, right now
The consultation closed on 7 Apr 2026 — it ran from 6 Feb 2026.
How it got here
Also on the Commission’s pipeline for this file, with no date recorded: Initiative planned.
15 positions
· · filed 7 Apr 2026 · source
EFFA / Industry Feedback on COM(2025) 747 Enhancing Regulatory Certainty and International Alignment through Quantitative Mixture Thresholds in Annex I and II EFFA welcomes the Commissions proposal for a Regulation on monitoring and controlling drug precursors and repealing Regulations (EC) No 273/2004 and (EC) No 111/2005: COM(2025) 747 final (3.12.2025).
· · filed 7 Apr 2026 · source
The cannabis industry association (BvCW) represents around 90 companies and professionals from all sectors of the cannabis industry and works to create responsible and safe cannabis markets. The BvCW welcomes the amendment of the Basic Substances Regulation and the corresponding possibility of issuing an opinion on (semi-)synthetic cannabinoids, industrial hemp and medicinal cannabis. 1.
Filed in German · English published by the European Commission
Fecc Feedback to Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on monitoring and controlling drug precursors and repealing Regulations (EC) No 273/2004 and (EC) No 111/2005. Fecc notes the above-mentioned proposal from the European Commission and welcomes the opportunity to provide feedback (see document attached).
The VCI strongly supports the European Commission’s objective of preventing the use of drug precursors for the illicit manufacture of drugs, while facilitating rules and procedures for legitimate trade. The German chemical-pharmaceutical industry supports the EU’s basic substance legislation and its implementation.
Filed in German · English published by the European Commission
· · filed 6 Apr 2026 · source
This initiative will revise the legislation on monitoring the trade in drug precursors between the EU and non-EU countries, and within the EU. It will cover a number of aspects which, following the recent evaluation of the regulatory framework, have shown a need for improvement, such as designer precursors through the study of substances that inhibit the desire for drugs.
Filed in Italian · English published by the European Commission
Cefic fully supports the Commissions work to strengthen the framework to prevent the misuse of drug precursors for illicit purposes, while reducing obstacles for legitimate trade. The EU chemical industry has a long-standing Responsible Care® commitment for safe, secure, responsible and sustainable production and use of chemicals, and shares the objective of ensuring that regulatory measures remain effective…
Chiron supports the overall objectives and initiative aims; in particular addressing the unnecessary obstacles to the free movement of licit drug precursors. We would recommend extension of the aims to also include illicit drug precursors used for valid scientific purposes.
The European Chemical Industry fully supports EU legislation regulating the trade of drug precursors both intra EU and with non-EU countries. Our support is in line with our industrys Responsible Care® commitment to ensure safe, secure, responsible, and sustainable production and use of chemicals.
· · filed 7 Jun 2023 · source
The German chemical-pharmaceutical industry supports EU legislation on raw materials and its implementation and considers the current legal framework overall appropriate, although there is a need for improvement in detail. Our member companies have been proactively and conscientiously fulfilling their responsibilities since 1991 through a national agreement on voluntary measures.
Filed in German · English published by the European Commission
· · filed 7 Jun 2023 · source
On behalf of the Ministry of Health of the Czech Republic, we propose to maintain the existing system of control and monitoring of conventional drug precursors, which would be supplemented by a new legal regulation that would apply purely to drug precursors without legal use. In principle, we thus support proposed option 3 (targeted regulation) or proposed option 4 (comprehensive regulation).
· · filed 6 Jun 2023 · source
Finnish Customs endorses the proposed amendment to the precursors legislation (in regulations related to both internal market and trade with 3rd countries). The amount of unregulated precursor chemicals and precursors of designer drugs currently found in Europe is significant also as stated in the proposal (in 2020, only 25% of confiscated precursors were of controlled substances).
· · filed 6 Jun 2023 · source
Designer precursors is a problem that the current legislation does not fully cover, so a targeted regulatory approach where the issue of designer precursors is included, is very favourable. Policy options 3 and 4 would create maximum impact. Norway has generic scheduling in the national narcotics regulation and considering a regulatory approach on EU-level where the same is done for precursors is very positive.
· · filed 6 Jun 2023 · source
The proposal to strenghten the regulations in the issue of designer precursors is considered important. Therefore the policy options 3 and 4 are the ones which could result in such strengthening. There still is room however for innovation in how perhaps modify the regulations for industry and users concerning specifically and only the substances without known legitimate uses and therefore leaving the regulations…
· · filed 16 May 2023 · source
The Netherlands agrees with the Commission that it is very important to tackle the problems we're facing with designer precursors. However we're of the opinion that the current legislative proposals will not adress the shortcomings identified in the evaluation of the EC regulations. Several designer precursors are listed in the EU regulations, as known those substances have no (or very little) legal uses.
· · filed 12 May 2023 · source
From a psychological point of view, it is highly advisable to implement option 1 as a matter of urgency. This can also be done in combination with one of the ‘stricter’ or broader regulatory approaches. Without raising awareness of the key role holder, stricter regulatory approaches will not be implemented or will be implemented only to a limited extent.
Filed in German · English published by the European Commission
Method. Every quote is verbatim from the organization’s own submission to the European Commission, trimmed to its opening passage and never summarized by a model. Where a submission was filed in another EU language we show the English text the European Commission publishes alongside it, labeled on the quote; the original is one click away at the source. Groupings use the respondent type the organization itself selected when filing. We deliberately do not label anyone “supportive” or “opposed” — you read what they wrote and draw your own conclusion. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.